Literature DB >> 25113646

Elevated serum CA 19-9 at screening tests: underlying conditions and role of abdominopelvic CT.

Ji Yang Kim1, Se Hyung Kim, Soo Young Kim.   

Abstract

OBJECTIVES: To investigate underlying conditions of patients with elevated CA 19-9 at screening tests and to evaluate diagnostic performance of abdominopelvic CT.
METHODS: One hundred and thirteen patients with elevated CA 19-9 (>37 U/ml) who underwent abdominopelvic CT in a screening program were selected. Underlying conditions were determined by reviewing all available data and follow-up records. Patients were categorized into malignancy, benign, and normal/non-related disease groups. Their mean CA 19-9 and percent of patients with CA 19-9 ≥ 100 U/ml were compared. Diagnostic sensitivity of CT for detecting underlying conditions of elevated CA 19-9 was analysed.
RESULTS: Seventeen patients (17/113, 15 %) had 17 elevated CA 19-9-related malignancies, and 55 patients (55/113, 48.7 %) had 70 benign diseases. Mean CA 19-9 and percent of patients with CA 19-9 ≥ 100 U/ml in the malignancy group were significantly higher than in the two other groups. CT detected all except one malignant lesion with a detection sensitivity of 94.1 % (16/17). Of 70 CA 19-9-related benign diseases, CT detected 34 benign diseases (48.6 %) providing an alternative diagnosis for elevated CA 19-9.
CONCLUSION: Abdominopelvic CT is not only useful in detecting malignancies, but can also diagnose alternative benign causes of elevated CA 19-9 in asymptomatic screening tests. KEY POINTS: • Fifteen percent of asymptomatic patients with elevated CA19-9 may have intra-abdominal malignancies. • Mean value of CA19-9 is different among malignant, benign, and non-related groups. • CT shows excellent sensitivity for intra-abdominal malignancies as causatives of elevated CA19-9. • CT provides alternative benign diagnoses as causatives of elevated CA19-9. • Detection of causatives of elevated CA19-9 using CT alleviates concerns and uncertainty.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25113646     DOI: 10.1007/s00330-014-3262-2

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  35 in total

1.  The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis.

Authors:  A H Patel; D M Harnois; G G Klee; N F LaRusso; G J Gores
Journal:  Am J Gastroenterol       Date:  2000-01       Impact factor: 10.864

2.  High level of preoperative carbohydrate antigen 19-9 is a poor survival predictor in gastric cancer.

Authors:  A Ra Choi; Jun Chul Park; Jie-Hyun Kim; Sung Kwan Shin; Sang Kil Lee; Yong Chan Lee; Jae Bock Chung
Journal:  World J Gastroenterol       Date:  2013-08-28       Impact factor: 5.742

3.  Low efficacy of serum levels of CA 19-9 in prediction of malignant diseases in asymptomatic population in Taiwan.

Authors:  Chi-Yang Chang; Shih-Pei Huang; Han-Mo Chiu; Yi-Chia Lee; Min-Fong Chen; Jaw-Town Lin
Journal:  Hepatogastroenterology       Date:  2006 Jan-Feb

4.  Mucosal expression of carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with gastritis and gastric cancer.

Authors:  G Esposito; A Tempesta; M G Galati; M de Bellis; G B Rossi; M I Potena; P Marone; B Daniele; S Del Vecchio
Journal:  Cancer Detect Prev       Date:  1999

Review 5.  Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer.

Authors:  K S Goonetilleke; A K Siriwardena
Journal:  Eur J Surg Oncol       Date:  2006-11-09       Impact factor: 4.424

6.  Immunohistochemical detection of carbohydrate determinant 19-9 (CA 19-9) in intracranial epidermoid and dermoid cysts.

Authors:  M Takeshita; O Kubo; Y Tajika; M Izawa; M Kagawa
Journal:  Surg Neurol       Date:  1993-10

7.  Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population.

Authors:  Jee-Eun Kim; Kyu Taek Lee; Jong Kyun Lee; Seung Woon Paik; Jong Chul Rhee; Kyoo Wan Choi
Journal:  J Gastroenterol Hepatol       Date:  2004-02       Impact factor: 4.029

8.  Increased CA 19-9 level in patients without malignant disease.

Authors:  Hye-Ryoun Kim; Chang-Hyun Lee; Young Whan Kim; Sung Koo Han; Young-Soo Shim; Jae-Joon Yim
Journal:  Clin Chem Lab Med       Date:  2009       Impact factor: 3.694

9.  CA19-9 as a screening and diagnostic tool in symptomatic patients: the Japanese experience.

Authors:  K Satake; T Takeuchi; T Homma; H Ozaki
Journal:  Pancreas       Date:  1994-11       Impact factor: 3.327

10.  Elevation of CA 19-9 and chromogranin A, in addition to CA 125, are detectable in benign tumors in leiomyomas and endometriosis.

Authors:  Kuo-Chien Tsao; Ji-Hong Hong; Tsu-Lan Wu; Pi-Yueh Chang; Chien-Feng Sun; James T Wu
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

View more
  2 in total

Review 1.  Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma.

Authors:  John C Chang; Madappa Kundranda
Journal:  Int J Mol Sci       Date:  2017-03-20       Impact factor: 5.923

2.  Usefulness of Carbohydrate Antigen 19-9 Test in Healthy People and Necessity of Medical Follow-up in Individuals with Elevated Carbohydrate Antigen 19-9 Level.

Authors:  Sang Pyo Lee; In-Kyung Sung; Jeong Hwan Kim; Sun-Young Lee; Hyung Seok Park; Chan Sup Shim
Journal:  Korean J Fam Med       Date:  2019-04-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.